IN2014DN09610A - - Google Patents

Info

Publication number
IN2014DN09610A
IN2014DN09610A IN9610DEN2014A IN2014DN09610A IN 2014DN09610 A IN2014DN09610 A IN 2014DN09610A IN 9610DEN2014 A IN9610DEN2014 A IN 9610DEN2014A IN 2014DN09610 A IN2014DN09610 A IN 2014DN09610A
Authority
IN
India
Prior art keywords
formula
ring
same
heteroatom
substituents
Prior art date
Application number
Other languages
English (en)
Inventor
Xiaodong Wang
Weihe Zhang
Dmitri Kireev
Dehui Zhang
Andrew Mciver
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of IN2014DN09610A publication Critical patent/IN2014DN09610A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN9610DEN2014 2012-05-22 2013-05-21 IN2014DN09610A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261650000P 2012-05-22 2012-05-22
PCT/US2013/042033 WO2013177168A1 (en) 2012-05-22 2013-05-21 Pyrimidine compounds for the treatment of cancer

Publications (1)

Publication Number Publication Date
IN2014DN09610A true IN2014DN09610A (enExample) 2015-07-31

Family

ID=49624289

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9610DEN2014 IN2014DN09610A (enExample) 2012-05-22 2013-05-21

Country Status (14)

Country Link
US (1) US9567326B2 (enExample)
EP (1) EP2852579A4 (enExample)
JP (1) JP2015517574A (enExample)
KR (1) KR20150018789A (enExample)
CN (1) CN104302627A (enExample)
AU (1) AU2013266438B2 (enExample)
BR (1) BR112014028424A2 (enExample)
CA (1) CA2873878A1 (enExample)
HK (1) HK1206338A1 (enExample)
IL (1) IL235726A0 (enExample)
IN (1) IN2014DN09610A (enExample)
MX (1) MX2014013632A (enExample)
RU (1) RU2014145121A (enExample)
WO (1) WO2013177168A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
AU2012318896B2 (en) 2011-10-03 2017-03-02 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
US9567326B2 (en) 2012-05-22 2017-02-14 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
WO2014058685A1 (en) * 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
CN104926801B (zh) 2014-03-22 2019-06-04 浙江大学 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
US20150291606A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrrolopyrimidine compounds
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3475263B1 (en) * 2016-06-27 2022-12-28 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and their use as irak4 inhibitors
CN106749173A (zh) * 2016-11-25 2017-05-31 吉林化工学院 一种嘧啶联吡啶类化合物的制备方法
WO2018203691A1 (ko) * 2017-05-02 2018-11-08 한국화학연구원 피리미딘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 tyro 3관련 질환의 예방 또는 치료용 조성물
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
EP3498694A1 (en) * 2017-12-12 2019-06-19 Medibiofarma, S.L. New benzamide derivatives as ppar-gamma modulators
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
KR102616469B1 (ko) * 2020-09-15 2023-12-28 주식회사 유엔에스바이오 혈액 순환 미세체외소체 매개 암 치료용 조성물
WO2022059996A1 (ko) * 2020-09-15 2022-03-24 서울대학교 기술지주 주식회사 혈액 순환 미세체외소체 매개 암 치료용 조성물
MX2023006434A (es) * 2020-12-16 2023-06-13 Abm Therapeutics Corp Inhibidores de quinasa y usos de los mismos.
CN119059982B (zh) * 2024-07-18 2025-09-19 河北科技大学 一种异羟肟酸类Mer/HDAC双靶点抑制剂及其制备方法和应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH549339A (de) * 1971-05-12 1974-05-31 Ciba Geigy Ag Herbizides mittel.
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
US20080248046A1 (en) 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
MXPA02010693A (es) * 2000-04-28 2003-03-10 Tanabe Seiyaku Co Compuestos ciclicos.
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
DE60228103D1 (de) 2001-10-02 2008-09-18 Smithkline Beecham Corp Chemische verbindungen
JP4529685B2 (ja) * 2002-06-28 2010-08-25 アステラス製薬株式会社 ジアミノピリミジンカルボキサミド誘導体
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
WO2004106339A2 (en) 2003-05-28 2004-12-09 Università Degli Studi Di Siena 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
BRPI0414533A (pt) 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
EP2233174B1 (en) 2004-01-21 2016-07-20 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
CA2553724A1 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
US7968557B2 (en) 2004-02-14 2011-06-28 Novartis Ag Substituted pyrrolo[2,3-2]pyrimidines as protein kinase inhibitors
EP1749827A4 (en) * 2004-03-30 2010-04-21 Kyowa Hakko Kirin Co Ltd ANTITUMOR AGENTS
WO2005099688A2 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1797069B1 (en) * 2004-09-30 2011-08-17 Tibotec Pharmaceuticals Hiv inhibiting 5-heterocyclyl pyrimidines
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
WO2007032445A1 (ja) * 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
EP1937258A2 (en) 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
CN101321751A (zh) * 2005-09-30 2008-12-10 布里斯托尔-迈尔斯·斯奎布公司 Met激酶抑制剂
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN101321759A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
EA017812B1 (ru) 2005-12-08 2013-03-29 Медарекс, Инк. Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение
EP1979002A2 (en) 2005-12-19 2008-10-15 OSI Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
EP1803723A1 (de) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
CN101405283B (zh) 2006-03-30 2014-06-18 泰博特克药品有限公司 Hiv抑制性5-酰氨基取代的嘧啶类化合物
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
CA2680122A1 (en) * 2007-03-05 2008-09-18 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
AU2008296479A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
HRP20110470T1 (hr) 2007-10-12 2011-07-31 Ingenium Pharmaceuticals Gmbh Inhibitori proteinskih kinaza
WO2010008411A1 (en) 2007-11-09 2010-01-21 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI458721B (zh) * 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US20120230991A1 (en) 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
US8569466B2 (en) 2008-09-10 2013-10-29 Nnochiri Ekwuribe Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers
UY32158A (es) * 2008-10-03 2010-04-30 Astrazeneca Ab Derivados heterociclicos y metodos de uso de los mismos
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US8765727B2 (en) 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
TW201102391A (en) 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
AR076550A1 (es) * 2009-05-06 2011-06-22 Portola Pharm Inc Inhibidores de la janus tirosina kinasa (jak)
EP3381937A3 (en) 2009-08-13 2018-10-31 The Johns Hopkins University Methods of modulating immune function
AU2010294209A1 (en) 2009-09-10 2012-03-29 Irm Llc Ether derivatives of bicyclic heteroaryls
WO2011065800A2 (ko) 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
AU2011330730B2 (en) 2010-11-18 2016-02-18 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
AU2012302197B2 (en) * 2011-08-29 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
JP5914667B2 (ja) 2011-09-22 2016-05-11 ファイザー・インク ピロロピリミジンおよびプリン誘導体
AU2012318896B2 (en) 2011-10-03 2017-03-02 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
US20160015808A1 (en) 2012-02-21 2016-01-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tam receptors as virus entry cofactors
TWI596089B (zh) * 2012-04-17 2017-08-21 富士軟片股份有限公司 含氮雜環化合物或其鹽
IN2012CH01573A (enExample) 2012-04-20 2015-07-10 Advinus Therapeutics Ltd
US9567326B2 (en) 2012-05-22 2017-02-14 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US20170202847A1 (en) 2014-04-04 2017-07-20 The University Of North Carolina At Chapel Hill Methods for the treatment of tumors
US20150291606A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrrolopyrimidine compounds

Also Published As

Publication number Publication date
AU2013266438B2 (en) 2017-09-07
EP2852579A1 (en) 2015-04-01
WO2013177168A1 (en) 2013-11-28
US20150038481A1 (en) 2015-02-05
AU2013266438A1 (en) 2014-12-04
RU2014145121A (ru) 2016-07-10
KR20150018789A (ko) 2015-02-24
HK1206338A1 (en) 2016-01-08
US9567326B2 (en) 2017-02-14
MX2014013632A (es) 2015-02-05
CA2873878A1 (en) 2013-11-28
JP2015517574A (ja) 2015-06-22
BR112014028424A2 (pt) 2018-04-24
EP2852579A4 (en) 2015-12-30
CN104302627A (zh) 2015-01-21
IL235726A0 (en) 2015-02-01

Similar Documents

Publication Publication Date Title
IN2014DN09610A (enExample)
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX367897B (es) Derivados de piridazinona macrociclicos.
PH12017500408A1 (en) Heteroaryl compunds as btk inhibitors and uses thereof
EP4458418A3 (en) Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
GEP20217330B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX2018005019A (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
EA030199B9 (ru) Терапевтически активные соединения и способы их применения
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
PH12016500225B1 (en) Novel quinoline-substituted compound
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
PH12016500643A1 (en) New octahydro - cyclobuta [1,2-c;3,4-c`] dipyrrol -2- yl
UA118666C2 (uk) Похідні піразолу
UA116239C2 (uk) Нові похідні піридину
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
PH12015501038A1 (en) Inhibitors of iap
MY170262A (en) Dicarboxylic acid compound
EP4585267A3 (en) Coumarin based hsp90 inhibitors with urea and ether substituents
UA112746C2 (uk) Протиракові стероїдні лактони, ненасичені в положенні 7(8)
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2016004509A (es) Compuestos que contienen nitrogeno y su uso.
MX2015011005A (es) Derivados de dihidorquinolin-2-ona para usarse como inhibidores de aldoesterona sintasa.